Exclusive articles:
MSCLF: AAK1 Disclosed as Drug Target for DMD Program…
By David Bautz, PhD
OTC:MSCLF
READ THE FULL MSCLF RESEARCH REPORT
Business Update
AAK1 Disclosed as Drug Target for DMD Program
On November 14, 2023, Satellos Biosciences Inc. (OTC:MSCLF)...
BCLI: FDA Meeting Provides Clear Path for Planned Phase 3b Trial of NurOwn
By David Bautz, PhD
NASDAQ:BCLI
READ THE FULL BCLI RESEARCH REPORT
Business Update
Clear Path Forward for Phase 3b Trial of NurOwn
On December 7, 2023, BrainStorm Cell Therapeutics,...
CVM: NICE To Have Your Support
By John Vandermosten, CFA
NYSE:CVM
READ THE FULL CVM RESEARCH REPORT
Multikine Selected as Potential New Standard of Care
CEL-SCI Corporation (NYSE:CVM) provided a pleasant surprise earlier this...
3 Reasons Why META Stock Will Stay a Winner in 2024
Over the past twelve months, shares in Meta Platforms (NASDAQ:META) have more than tripled in price. After such outsized performance, the question now is...
Gen Z Growth Picks: 3 Stocks Capturing the Next Generation’s Attention
While the past several years have focused on the whims and desires of millennials, it’s time to shift this paradigm by focusing largely on...
